New drug vs standard chemo for HER2-positive endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial compares a new targeted medicine (trastuzumab deruxtecan) against standard chemotherapy for women with a certain type of advanced endometrial cancer that has high levels of HER2 protein. It's for people whose cancer is newly diagnosed and has spread to nearby tissues but not to distant organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a type of endometrial cancer that is not a sarcoma (carcinosarcoma is allowed).
- Your cancer is newly diagnosed and is at a stage called Stage IIC or Stage III (not stage IV or cancer that has come back after treatment).
- A central lab has confirmed that your cancer cells have high levels of HER2 protein (a score of 2+ or 3+).
- You have a tumor tissue sample from surgery available for testing.
- You do not have certain heart or lung conditions, or a history of serious lung inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs for endometrial cancer that has spread or come back. It aims to see if these drugs can shrink tumors and help people live longer. It is for tumors that have a certain protein (HER2) and are mismatch repair proficient (meaning they have a normal DNA repair system).
This trial compares giving trastuzumab-deruxtecan before surgery versus standard chemotherapy plus trastuzumab and pertuzumab. It aims to see which approach works better to shrink or control HER2-positive early breast cancer and improve outcomes.
This trial tests whether a targeted drug called trastuzumab deruxtecan can help people with advanced HER2-positive stomach, esophageal, or gastroesophageal junction cancer. It's for those who haven't had chemotherapy for metastatic disease and are not able to get combination therapy.
This trial tests if a newer drug, Trastuzumab Rezetecan, works as well as an approved drug, Trastuzumab Deruxtecan, when given before surgery for HER2-positive breast cancer. It aims to see which one helps shrink tumors more effectively.
This trial is testing a new medicine as the first treatment for HER2-positive breast cancer that has spread or cannot be removed. It's for women who have not had chemotherapy for advanced disease.
This trial tests a combination of two drugs, trastuzumab deruxtecan (SHR-A1811) and pertuzumab, given before surgery to shrink HER2-positive breast cancer. It is for women with stage II or III breast cancer who have not yet had treatment and are in good overall health.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.